Autopsy report · NCT05097599

StrataPATH™ (Precision Indications for Approved Therapies)

“Business decision and enrollment difficulties”

The sponsor’s own words in the registry.

Life of this trial

• Registered 7 months before it started.
• Ran for about 2 years 1 month before it stopped.
• 11 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

Strata Oncology

Sponsor type

Industry

Conditions

Cancer; Advanced Solid Tumor

Interventions

lorlatinib; encorafenib + binimetinib; talazoparib; sacituzumab govitecan; axitinib; Fam-Trastuzumab Deruxtecan-Nxki

Participants

11

Sites

4

Countries

United States

Trials that died the same way

• A Study to Evaluate the Renal Protective Effect (Urine Albumin-to-Creatinine Ratio (UACR)), Efficacy and Safety of Ipragliflozin in Type 2 Diabetes Mellitus Patients With Albuminuria
  “Business decision due to enrollment challenges” (86% match in meaning)
• AVAD: Asthma With Small Airways Dysfunction
  “difficulties of enrollment” (86% match in meaning)
• Clinical Trial With Mesalamine 1g Suppositories
  “Enrollment difficulties” (84% match in meaning)
• The Safety of Transdermal Nicotine Immediately Following an Acute Coronary Syndrome
  “Difficulties with enrollment.” (83% match in meaning)
• A Prospective, Single-center, Randomized, Controlled Study of Sevelamer Carbonate in the Lipid Metabolism and Uric Acid Treatment of Obesity-Related Glomerulopathy
  “difficulty in enrollment” (81% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.